PCOS renamed to PMOS: what the global nomenclature shift means for Canadian patients

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

What happened

A 2026 correspondence published in The Lancet proposes retiring the name polycystic ovary syndrome (PCOS) in favour of polycystic metabolic and ovulatory syndrome (PMOS), arguing that the current name misdirects both patients and clinicians toward the ovaries when the condition's defining features are metabolic and hormonal. For the roughly one in ten Canadian women and people with ovaries affected by this condition, the proposal raises an immediate practical question: does a name change alter how they will be diagnosed, treated, or covered under provincial health plans?

The short answer, for now, is no. Health Canada has not issued any regulatory guidance tied to the proposed renaming, and the Society of Obstetricians and Gynaecologists of Canada (SOGC) has not yet released a position statement on PMOS as a clinical term. Provincial billing codes, drug coverage under plans like OHIP (Ontario Health Insurance Plan), RAMQ (Régie de l'assurance maladie du Québec), MSP (British Columbia's Medical Services Plan), and AHCIP (Alberta Health Care Insurance Plan) all continue to reference PCOS. Until those frameworks are updated, Canadian patients will still see PCOS on their charts, referral letters, and insurance forms.

Why this matters

PCOS is the most common endocrine disorder in people with ovaries, affecting an estimated 8 to 13 percent of reproductive-age women globally, according to the World Health Organization. In Canada, that translates to hundreds of thousands of patients navigating a condition that is frequently misunderstood, underdiagnosed, and inconsistently managed across provinces.

The core argument in the Lancet correspondence is that the word "polycystic" is misleading. Many people diagnosed with PCOS do not have cysts in the traditional sense; what imaging detects are multiple small follicles, not fluid-filled cysts. The word "ovary" in the name further implies the problem originates in the ovaries, when the underlying drivers are more accurately described as insulin resistance, androgen excess, and disrupted ovulation. The authors argue that PMOS better captures this reality: the "M" for metabolic, the "O" for ovulatory dysfunction, and the retention of "polycystic" as a nod to the imaging findings that remain part of the Rotterdam diagnostic criteria.

This is not the first time the name has come under scrutiny. A 2023 international consensus process, which included input from patient advocates and clinicians across multiple countries, found that a majority of patients and healthcare providers supported renaming the condition. That process, reported in The Journal of Clinical Endocrinology and Metabolism, found that the current name caused confusion, stigma, and delayed diagnosis.

What this means in Canada

Health Canada classifies PCOS as a condition rather than a drug or device, so a name change does not require a regulatory approval process in the way a new medication would. However, the Canadian Medical Association Journal (CMAJ) and the SOGC both play a role in translating international nomenclature shifts into Canadian clinical practice. Neither body has formally adopted PMOS as of July 2026.

For provincial drug coverage, the name change matters indirectly. Medications commonly used to manage PCOS symptoms include metformin (sold in Canada as Glucophage and various generics), which is covered under most provincial formularies for diabetes but not always for PCOS specifically, and combined oral contraceptives, which are covered variably by province. Spironolactone, used off-label for androgen-related symptoms like hirsutism and acne, is listed on most provincial formularies but coverage for PCOS indications differs by province. A renaming to PMOS would not automatically change formulary listings; those require separate provincial decisions.

Canadian telehealth platforms that offer hormone care, including Cleo (a Canadian women's-health platform), Felix, and Science and Humans (scienceandhumans.com), currently use PCOS in their intake and clinical documentation. Maple and Telus Health similarly follow existing diagnostic terminology. Patients using these services should not expect their records or treatment plans to change until Canadian clinical bodies formally adopt new terminology.

What Canadian patients should know

If you have a PCOS diagnosis, nothing about your treatment changes because of this proposal. The Rotterdam criteria, which require two of three features (irregular ovulation, elevated androgens, and polycystic ovarian morphology on ultrasound) to make a diagnosis, remain the standard used by Canadian clinicians.

What may change over the next few years is how your condition is explained to you. A shift to PMOS, if adopted, would reframe the conversation away from ovarian appearance and toward metabolic health, which many clinicians and patient advocates argue is where the clinical focus belongs. Insulin resistance, for example, is present in an estimated 50 to 70 percent of people with PCOS regardless of body weight, yet it is not always assessed at diagnosis in Canadian primary care settings.

Patients in provinces with limited access to endocrinologists or gynecologists may find that a clearer name helps them advocate for metabolic screening, including fasting glucose, HbA1c, and lipid panels, at their family physician's office. The SOGC's existing guidance on PCOS does recommend metabolic screening, though implementation varies.

If you are newly diagnosed or seeking a second opinion, Canadian clinics offering hormone-focused care include those listed above. US-based platforms such as Midi Health and Winona do not serve Canadian patients.

Limitations and open questions

The Lancet piece is a correspondence, not a clinical trial or a guideline. It represents the authors' perspective and does not carry the weight of a consensus statement from a clinical society. The SOGC has not yet issued a position on PMOS. Health Canada has not commented. The Canadian Institutes of Health Research (CIHR) has not announced funding for Canadian-specific research into the nomenclature shift's effect on diagnosis rates or patient outcomes.

It is also unclear whether a name change alone improves outcomes. Renaming a condition can reduce stigma and improve diagnostic clarity, but the evidence base for that claim in the PCOS context is still thin. The 2023 international consensus found patient support for renaming, but support is not the same as demonstrated clinical benefit.

What the proposal does, at minimum, is prompt a conversation that Canadian patients and their clinicians should be having regardless of what the condition is eventually called: is the metabolic dimension of this diagnosis being assessed and treated, not just the reproductive one?